REINVENTING HOW HEALTHCARE PROFESSIONALS AND PATIENTS MANAGE PAIN
Pain is a universal condition, while the perception of pain is unique. Virpax Pharmaceuticals is committed to developing non-addictive product candidates that manage pain and its complexities, while providing treatment options and minimizing risks to patients and society. By combining selected drug compounds with our cutting‑edge delivery systems, we strive to maximize our products’ capabilities and successfully bring them to market. We believe our proprietary delivery systems will reinvent how patients and prescribers manage pain worldwide.
NON-ADDICTIVE PRODUCTS
We are advancing drug development strategies that will address the prominent need for non‑addictive alternatives in treatment of pain and CNS disorders. Our Molecular Envelope Technology (MET), topical spray film technology, and liposomal hydrogel technology will significantly improve our drug delivery characteristics by directly targeting pain symptoms and CNS Disorder symptoms at their source.
CNS GROWTH OPPORTUNITIES
Our MET platform is being used to grow our Central Nervous System (CNS) disorder pipeline. These additional patented formulations may include neurotransmission and neuroprotective actives. The current product candidates include Post Traumatic Stress Disorder (PTSD), and Rare Pediatric Epilepsy. In the future, the MET will be used to deliver actives that will be developed to manage other neurodegenerative disorders.
“Biopharma companies have a deep understanding of the R&D of novel products, making the industry essential to the advancement of public health initiatives.”
ANTHONY P. MACK
CEO of Virpax Pharmaceuticals
Prescribers, regulators, and patients are seeking non-addictive treatment options to combat the opioid epidemic.
The FDA is fostering the development of non-addictive alternatives to opioids for acute pain management.
We are continuously strengthening our worldwide patents in the development of non-addictive treatments for pain and degenerative neurological disorders.
We are seeking FDA approval for a robust pipeline of product candidates that will radically change how clinicians prescribe pain and CNS disorder therapies in the future.
